SCHEMBL3323951

SCHEMBL3323951

CC1=C(C(=O)OCCOc2ccccc2)C(c2ccc(Cl)cc2Cl)C2=C(CC(C)(C)CC2=O)N1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 16/20 0.70
ALDH1A1 P00352 13/20 0.70
HSD17B10 Q99714 7/20 0.70
HPGD P15428 7/20 0.70
NPSR1 Q6W5P4 3/20 0.70
TP53 P04637 1/20 0.70
CASP1 P29466 6/20 0.53
CASP7 P55210 5/20 0.53
ALOX15 P16050 1/20 0.53
MAPK1 P28482 1/20 0.53
GAA P10253 9/20 0.52
GLA P06280 3/20 0.52
TSHR P16473 2/20 0.52
USP2 O75604 1/20 0.50
PKM P14618 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
RECQL P46063 1/20 0.47
NOTCH1 P46531 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3326289 0.91 KDM4E (0.74) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL23008930 0.91 KDM4E (0.57) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL3326470 0.88 KDM4E (0.71) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL3324672 0.87 KDM4E (0.63) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL3324485 0.84 KDM4E (0.73) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL3324683 0.83 KDM4E (0.69) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL3325287 0.83 KDM4E (0.72) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL3327896 0.83 KDM4E (0.73) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL3320497 0.82 KDM4E (0.71) KDM4EALDH1A1HSD17B10HPGDNPSR1
SCHEMBL3320698 0.82 KDM4E (0.60) KDM4EALDH1A1HSD17B10HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION APP, MAPT, PSEN1 KDM4E 4115/4885ALDH1A1 2615/4885HSD17B10 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.